Elutia Inc. (Nasdaq: ELUT), a leader in drug-eluting biomatrix technology, has received two major honors at the 2025 Medical Device Network Excellence Awards. The company was recognized in the categories of Innovation and Product Launches for its work on advanced drug-eluting bioenvelopes and the successful rollout of its EluPro product.
“We’re honored to receive recognition in both categories,” said Dr. Randy Mills, CEO of Elutia. “These awards represent the combined efforts of our scientists and our commercial team. Neither group could have succeeded alone. Their work reflects our CRU values—from the first idea to getting the product to market. That’s what makes EluPro a success.”